Sunshine Biopharma Inc. - Common stock (SBFM)
0.2541
+0.00 (0.00%)
NASDAQ· Last Trade: May 30th, 9:45 AM EDT
Detailed Quote
| Previous Close | - |
|---|---|
| Open | - |
| Bid | 0.2424 |
| Ask | 0.2425 |
| Day's Range | 0.2500 - 0.3042 |
| 52 Week Range | 0.2500 - 2.430 |
| Volume | 6,735,441 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 37,427,203 |
Chart
About Sunshine Biopharma Inc. - Common stock (SBFM)
Sunshine Biopharma is a biotechnology company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. With a commitment to advancing medical research, the company is engaged in the discovery and commercialization of novel drug compounds, specifically targeting unmet medical needs. Sunshine Biopharma utilizes a combination of advanced scientific techniques and proprietary technologies to create effective treatments, working towards improving the quality of life for patients affected by challenging health conditions. Their research initiatives aim to provide new hope in the fight against various forms of cancer, emphasizing the importance of scientific innovation in medicine. Read More
News & Press Releases
FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.
Via ACCESS Newswire · May 29, 2026
Thursday's session: top gainers and loserschartmill.com
Via Chartmill · May 28, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · May 28, 2026
Which stocks are gapping on Thursday?chartmill.com
Via Chartmill · May 28, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 21,236,346 to approximately 2,123,635.
Via ACCESS Newswire · May 28, 2026
A number of actively traded small-cap and growth stocks are drawing increased investor attention as momentum continues building across sectors tied to AI infrastructure, biotechnology, GLP-1 healthcare, vaccines, high-performance computing, and digital infrastructure. Names currently trading actively include ENDRA Life Sciences Inc. (NASDAQ: NDRA), Sunshine Biopharma Inc. (NASDAQ: SBFM), GeoVax Labs Inc. (NASDAQ: GOVX), HIVE Digital Technologies Ltd. (NASDAQ: HIVE), and Sphere 3D Corp. (NASDAQ: ANY).
Via AB Newswire · May 26, 2026
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is gaining increasing investor attention as the company advances its TAEUS® Liver imaging platform while simultaneously evaluating strategic alternatives aimed at maximizing shareholder value.
Via AB Newswire · May 26, 2026
Investors searching for stocks under $1 with breakout potential, AI exposure, biotech catalysts, streaming growth, and emerging healthcare innovation are increasingly focusing on a group of small-cap companies gaining momentum across multiple high-growth sectors. Companies drawing attention include Kartoon Studios (NYSE: TOON), Virax Biolabs Ltd (NASDAQ: VRAX), NextNRG Inc. (NASDAQ: NXXT), AIM ImmunoTech Inc. (NYSE: AIM), and Sunshine Biopharma Inc. (NASDAQ: SBFM).
Via AB Newswire · May 26, 2026
What's going on in today's after hours sessionchartmill.com
Via Chartmill · May 21, 2026
Most active stocks in Thursday's sessionchartmill.com
Via Chartmill · May 21, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · May 21, 2026
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · May 21, 2026
Sunshine Biopharma (NASDAQ: SBFM) shares are trading higher Thursday after securing Canadian regulatory approval for generic amoxicillin.
Via Benzinga · May 21, 2026
What's going on in today's pre-market sessionchartmill.com
Via Chartmill · May 21, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Amoxicillin formulation for the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.
Via ACCESS Newswire · May 21, 2026
Top movers in Wednesday's sessionchartmill.com
Via Chartmill · May 20, 2026
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering
Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses through the sale of 12 million common units, each including common stock or pre-funded warrants and two Series C warrants. The company said net proceeds will be used for general corporate purposes and working capital, with potential additional gross proceeds of approximately $12 million if the Series C warrants are fully exercised for cash, while Aegis Capital acted as exclusive placement agent.
Via Investor Brand Network · May 20, 2026
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
Via Chartmill · May 20, 2026
In today's session, these stocks are experiencing unusual volume.chartmill.com
Via Chartmill · May 19, 2026
$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants.
Via ACCESS Newswire · May 19, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.
Via ACCESS Newswire · May 18, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
Via ACCESS Newswire · April 6, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many in the crowd. On Tuesday, the company announced that it had secured Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary, a milestone that not only expands its commercial reach but also validates its growing track record of revenue-generating execution.
Via ACCESS Newswire · October 28, 2025
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced that its wholly owned subsidiary, Nora Pharma Inc., has received approval from Health Canada, the Canadian equivalent to the FDA, for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance gastrointestinal motility.
Via ACCESS Newswire · October 28, 2025
FORT LAUDERDALE, FL, QC / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company's footprint in the Canadian growing antibiotic sector. Doxycycline is now available to pharmacies, hospitals and healthcare providers nationwide.
Via ACCESS Newswire · October 20, 2025